VKTX - Viking Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $98.20 DETAILS

Stock News

VKTX Down 16% in a Month: Time to Invest or Exit the Stock?

Viking Therapeutics faces dilution and rising obesity competition, but VK2735's pipeline progress could offer catalysts and support a rebound.

Oct 06, 2026 06:16 AM • zacks.com

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735 Monthly and Every-Other-Week Subcutaneous Regimens to also be Evaluated SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of an exploratory oral maintenance dosing study of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.

Oct 06, 2026 03:05 AM • prnewswire.com

Here Are My Top 4 Stocks to Buy in October

Get 'em while they're still on sale. Catalysts are on the horizon.

Oct 05, 2026 04:24 AM • fool.com

LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies

Eli Lilly's new data show Foundayo's cardiovascular safety and metabolic benefits, while EloraTZP delivers greater weight loss and A1C reduction in a mid-stage study.

Oct 02, 2026 06:16 AM • zacks.com

Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?

Viking Therapeutics raised $575 million in a supplementary public offering after positive trial results. Share dilution reduces EPS by about 7.2%, and the earnings yield per dollar invested is now 14.4% lower.

Oct 02, 2026 04:00 AM • fool.com

Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $30.51, moving 6.41% from the previous trading session.

Oct 01, 2026 02:46 PM • zacks.com

Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy

Could this be what Novo needs to turn things around?

Sep 30, 2026 03:10 PM • fool.com

Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $32.74, signifying a +2.92% move from its prior day's close.

Sep 30, 2026 02:50 PM • zacks.com

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

Viking Therapeutics' leading candidate recently performed well in a maintenance clinical trial. The medicine could eventually become a notable player in the weight-loss market.

Sep 30, 2026 01:00 PM • fool.com

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.

Viking Therapeutics' recent clinical trial results for its leading weight loss candidate were excellent. But Eli Lilly, the leader in this area, has a robust pipeline of its own and has little to fear from its smaller rival.

Sep 29, 2026 01:30 PM • fool.com

3 Non-AI Growth Stocks That Have Massive Upside

Investors looking for some compelling growth opportunities outside of tech may want to consider these stocks.

Sep 29, 2026 07:00 AM • fool.com

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes

Gross Proceeds to Viking Approximately $575 Million SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its concurrent upsized public offerings of 9,035,714 shares of common stock, at a public offering price of $35.00 per share, and $258.75 million aggregate principal amount of 2.00% convertible senior notes due 2032 (the "notes"), which included the full exercise by the underwriters of the common stock offering of their option to purchase an additional 1,178,571 shares of common stock, and the full exercise by the underwriters of the note offering of their option to purchase an additional $33.75 million aggregate principal amount of notes.

Sep 28, 2026 12:30 PM • prnewswire.com

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law FirmPR NewswireNEW YORK, Sept. 28, 2026NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn

Sep 28, 2026 08:00 AM • gurufocus.com (Hide legal announcements)

Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver

Viking Therapeutics delivered strong VK2735 maintenance trial results in obesity, showing robust induced weight loss and promising tolerability with less frequent dosing in the maintenance phase. VKTX demonstrated competitive or superior efficacy to Eli Lilly's tirzepatide and retatrutide across comparable time points, with tolerability expected to improve in phase 3 with less aggressive titration. The $500 million equity and convertible note offering temporarily pressured shares but was a necessary step to support advancing VKTX's pipeline and future spending.

Sep 28, 2026 07:56 AM • seekingalpha.com

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders.

Sep 28, 2026 07:12 AM • prnewswire.com (Hide legal announcements)

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Sep 28, 2026 06:31 AM • zacks.com

Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?

Eli Lilly's high valuation could limit the stock's future returns. Viking Therapeutics is a much smaller company, and it has a promising GLP-1 asset in VK2735.

Sep 28, 2026 05:01 AM • fool.com

Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution

The drug candidate's subcutaneous results are strong, but oral formulation data is still pending. The upcoming oral maintenance trial results are crucial to VKTX's dual-formulation strategy.

Sep 27, 2026 06:00 AM • fool.com

3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing

The company's key drug continues to demonstrate it can produce rapid weight loss in people with obesity. The maintenance dosing data support its potential to generate sustained weight loss for patients.

Sep 27, 2026 12:55 AM • fool.com

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?

Viking is testing weight loss drug candidates in late-stage trials. The company recently showed that weight loss lasts after taking its drug candidate.

Sep 25, 2026 02:05 AM • fool.com